

29 June 2025

To,

The Board of Directors,
JB Chemicals & Pharmaceuticals Limited
Cnergy IT Park,
Unit A2, 3rd floor & Unit A, 8th floor,
Appa Saheb Marathe Marg,
Prabhadevi,
Mumbai - 400025

Sub: Fairness opinion to the Board of Directors of JB Chemicals & Pharmaceuticals Limited (“JB Chemicals” or “Company” or “Transferor Company”) on Recommendation of the Share Exchange Ratio for the proposed merger of JB Chemicals with Torrent Pharmaceuticals Limited (“Torrent Pharma” or “Transferee Company”) (Transferor Company and Transferee Company collectively referred to as “Companies”), in relation to the Scheme of Amalgamation (“Scheme”) of JB Chemicals with Torrent Pharma and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 (“Proposed Transaction”)

In terms of our engagement entered into with JB Chemicals, JB Chemicals has requested ICICI Securities (I-Sec) to provide a fairness opinion to the Board of Directors of JB Chemicals on Recommendation of the Share Exchange Ratio for the proposed merger in relation to the Scheme of Amalgamation of JB Chemicals with Torrent Pharma and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013.

BACKGROUND, PURPOSE AND USE OF THIS FAIRNESS OPINION

JB Chemicals, incorporated in 1976, is engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations, herbal remedies and Active Pharmaceutical Ingredients (APIs). It has 8 state-of-the-art multi-dosage formulation plants with its presence in 40+ regulated and semi-regulated markets through direct operations and distributors. The equity shares of JB Chemicals are listed on NSE and BSE.

Torrent Pharma, incorporated in 1972, is engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. It is the flagship company of Torrent Group which also has presence in power and city gas distribution business. It has a global presence across 40+ countries, serviced through its 8 manufacturing units across India. The equity shares of Torrent Pharma are listed on NSE and BSE.

The Proposed Transaction shall be undertaken post the acquisition of shares held by Tau Investment Holdings Pte. Limited (74,481,519 shares) in JB Chemicals by Torrent Pharma, followed by an open offer.

The Proposed Scheme under Section 230 to 232 and other applicable provisions of the Companies Act, 2013 (“**the Cos Act**”) and the rules and regulations made thereunder *inter alia* provide for merger of JB Chemicals with Torrent Pharma with effect from the Appointed Date i.e. date on which the



Transferee Company completes the acquisition of 74,481,519 fully paid equity shares of the Transferor Company from the promoters of the Transferor Company.

The Company has appointed **BDO Valuation Advisory LLP**, as **Registered Valuer** and we understand that Torrent Pharma has appointed Ernst & Young Merchant Banking Services LLP as Registered Valuer to determine and recommend the Share Exchange Ratio for the Proposed Transaction, with 28 June 2025 being the valuation date. In this connection, pursuant to the requirements of SEBI Master Circular SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated 20 June 2023 (as updated), we have been requested by the Board of Directors of JB Chemicals to render a fairness opinion on recommendation of ratio being proposed in relation to the Proposed Transaction as recommended by the Registered Valuer vide its valuation report dated 29 June 2025.

The Registered Valuer have recommended the following Share Exchange Ratio for the Scheme:

Share Exchange ratio in the event of merger of JB Chemicals into Torrent Pharma:

"51 (Fifty-One) equity shares of Torrent Pharmaceuticals Limited of INR 5/- each fully paid up for every 100 (Hundred) equity shares of JB Chemicals & Pharmaceuticals Limited of INR 1/- each fully paid up"

This fairness opinion is intended only for the sole use and information of the Board of Directors of JB Chemicals and only in connection with the Proposed Transaction. We are not responsible in any way to any other person / party for any decision of such person or party based on this fairness opinion. Any person / party intending to provide finance / invest in the shares / business of any of the companies involved in the Proposed Transaction or their subsidiaries / joint ventures / associates shall do so after seeking their own professional advice and after carrying out their own due diligence procedures to ensure that they are making an informed decision. It is hereby notified that any reproduction, copying or otherwise quoting of this fairness opinion or any part thereof, other than in connection with the Proposed Transaction as aforesaid can be done only with our prior permission in writing.

SOURCES OF INFORMATION

In arriving at our opinion set forth below, we have relied on:

1. Draft Scheme of Amalgamation for the Proposed Transaction;
2. Annual reports of the Companies for years ended 31 March 2020 to 31 March 2024;
3. Audited consolidated financials (balance sheet and profit and loss account along with schedules) of JB Chemicals and Torrent Pharma for the period ended 31 March 2025;
4. Financial projections of the Companies on a consolidated basis from 1 April 2025 to 31 March 2030 (including forecast of profit and loss statements, capital expenditure and working capital requirements);
5. Consideration for purchase of all the equity shares held by Tau Investment Holdings Pte. Ltd. (KKR) in JB Chemicals agreed independently between Torrent Pharma and JB Chemicals;
6. Details of number of outstanding shares on fully diluted basis of the Companies as on the Valuation Date [including Employee Stock Options (ESOPs) and expected payoff / settlements];
7. Details of contingent liabilities for the Companies;
8. Market prices of JB Chemicals and Torrent Pharma as published by NSE;



9. Obtained and analyzed data of peers available in public domain (including from Bloomberg), as deemed relevant by us for the purpose of the present exercise;
10. Discussion with the Management of the Companies in connection with the operations of the respective Companies/ subsidiaries/ investee companies, past and present activities and future plans and prospects;
11. Other relevant information and documents for the purpose of this engagement provided through emails or during discussions

SCOPE LIMITATIONS

Our fairness opinion is subject to the scope limitations detailed hereinafter. As such the fairness opinion is to be read in totality, and not in parts, in conjunction with the relevant documents referred to therein.

Our work does not constitute an audit, due diligence or certification of the historical financial statements in relation to the Companies including their respective working results or businesses referred. Accordingly, we are unable to and do not express an opinion on the accuracy of any financial information referred to in this fairness opinion. Our analysis and results are specific to the purpose of the exercise of giving our fairness opinion as described hereinabove. It may not be valid for any other purpose or if provided on behalf of any other entity. Our fairness opinion is addressed to and is solely for the benefit of the Board of Directors of JB Chemicals and should not be publicly or otherwise circulated, provided or disclosed to any person, authority (including regulatory authority), entity or any public or private platform without our prior written consent. No other person, entity or regulatory authority shall, save with our written consent, rely on this opinion or any part thereof.

We have considered financial information in our analysis and have made adjustments for facts made known to us till the date of our report, including taking into consideration current market parameters. An exercise of this nature involves consideration of various factors. This fairness opinion is issued on the understanding that each of the Companies have drawn our attention to all the matters which may have an impact on our opinion including any significant changes that have taken place or are likely to take place in the financial position or businesses up to the date of approval of the Scheme by the Board of Directors. We have no responsibility to update this fairness opinion for events and circumstances occurring after this date.

In the course of the present exercise, we were provided with both written and verbal information, including financial data. The terms of our engagement were such that we were entitled to rely upon the information provided without detailed inquiry. Also, we assume that the management of each of the Companies, has not omitted any relevant and material factors for the purposes of the work which we have undertaken in connection with this fairness opinion.

We shall have no obligation to verify the accuracy or completeness of any information or express any opinion or offer any form of assurance regarding the accuracy or completeness of such information and shall not assume any liability therefor. We assume no responsibility whatsoever for any errors in the information furnished to us and their impact on the present exercise.

We express no opinion whatsoever and make no recommendation at all to the shareholders or secured or unsecured creditors of each of the Companies, as to how they should vote at their respective meetings held in connection with the Scheme. We do not express and should not be deemed to have expressed any views on any other term of the Scheme. We also express no opinion and accordingly accept no responsibility with respect to the financial performance of the Companies following the consummation

of the Scheme. We also express no opinion on the likely market price of the Companies post the consummation of the Scheme.

No investigation with respect to the claim to title of assets of each of the Companies has been made for the purpose of this exercise and the same has been assumed to be valid. We have not placed any individual value on the assets of each of the Companies and have also not considered any liens or encumbrances on the same. Further we have not opined and accordingly do not take responsibility whatsoever for matters of a legal nature. Also, we are not opining on matters related to taxation. This fairness opinion should not be construed as a certification regarding the compliance of the Scheme with the provisions of any law including Companies Act, tax laws and capital market related laws or as regards any legal implications or issues arising from the Scheme.

In the ordinary course of business, ICICI Securities Limited and its affiliates is engaged in securities trading, securities brokerage and investment activities, as well as providing investment banking and investment advisory services. In the ordinary course of its trading, brokerage and financing activities, any member of ICICI Securities Limited may at any time hold long or short positions, and may trade or otherwise effect transactions, for its own account or the accounts of customers, in debt or equity securities or senior loans of any company that may be involved in the Scheme.

In arriving at our opinion, we have assumed and relied upon, without any independent verification or validation, the accuracy and completeness of the financial and other information and data publicly available or provided to or otherwise reviewed by or discussed with us and have relied upon the assurances of the management of JB Chemicals and Torrent Pharma that they are not aware of any facts or circumstances that would make such information or data inaccurate or misleading in any material respect. With respect to the financials and forecasts, we have been advised by JB Chemicals and Torrent Pharma, and have assumed, that: (i) they have been reasonably prepared and/or confirmed on bases reflecting the best currently available estimates and good faith judgements of the management of JB Chemicals and Torrent Pharma as to the future financial performance of the Companies or their respective subsidiaries and/or associates, and (ii) they are based on the understanding of the management of JB Chemicals and Torrent Pharma of the current business strategy, operations, competition and macro-economic indicators and involves known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by the financials and forecast of the Companies or their respective subsidiaries and/or associates.

Without limiting the generality of the foregoing, we have also assumed, at the direction of JB Chemicals and Torrent Pharma, their respective subsidiaries and associates, as applicable, will receive all statutory clearances with respect to their respective operations in accordance with the assumptions regarding such clearances in their financials and forecasts.

We have been informed by the management of JB Chemicals and Torrent Pharma that the financials and forecasts provided to us have been prepared in accordance with Indian Accounting Standards (Ind-AS). We have not made or been provided with any independent evaluation or appraisal of the assets or liabilities (contingent or otherwise) of the Companies or their respective subsidiaries and/or associates, as applicable, and/or any other entity (other than the Valuation Report, which we have reviewed and relied upon without independent verification for purposes of this opinion), nor have we made any physical inspection or title verification of the properties or assets of the Companies, their respective subsidiaries and/or associates, as applicable, and/or any other entity, and we do not express any opinion as to the value of any asset of the Companies, their respective subsidiaries and/or associates, as

applicable, and/or any other entity, whether at current prices or in the future. We have not evaluated the solvency or fair value of the Companies, their respective subsidiaries and/or associates, as applicable, and/or any other entity under the laws of India or any other laws relating to bankruptcy, insolvency or similar matters.

We have assumed, at the direction of JB Chemicals, that the Proposed Transaction will be consummated in accordance with its terms, without waiver, modification or amendment of any material term, condition or agreement and that, in the course of obtaining the necessary governmental, judicial, regulatory and other approvals, consents, releases and waivers for the Proposed Transaction, no delay, limitation, restriction or condition, including any divestiture requirements or amendments or modifications, will be imposed that would have an adverse effect on JB Chemicals, their respective subsidiaries and/or associates, as applicable, and/or any other entity or the contemplated benefits of the Proposed Transaction. We also have assumed, at the direction of JB Chemicals, that the final executed Scheme will not differ in any material respect from the Draft Scheme reviewed by us.

We have not undertaken any independent analysis of any potential or actual litigation, regulatory action, possible unasserted claims, or other contingent liabilities, or any settlements thereof, to which JB Chemicals, their respective subsidiaries and/or associates, as applicable, and/or any other entity, are or may be a party or are or may be subject, and this opinion does not consider the potential effects of any such litigation, actions, claims, other contingent liabilities or settlements.

We express no view or opinion as to any terms or other aspects or implications of the Proposed Transaction (other than the Ratios to the extent expressly specified herein), including, without limitation, the form or structure of the Proposed Transaction, the taxation impact of the Proposed Transaction or the Equity Shares issued and allotted under the Proposed Transaction or any terms or other aspects or implications of any other agreement, arrangement or understanding entered into in connection with or related to the Proposed Transaction or otherwise. We were not requested to, and we did not, participate in the negotiation of the terms of the Proposed Transaction. Our opinion does not address any matters otherwise than as expressly stated herein, including but not limited solely to matters such as corporate governance, shareholder rights or any other equitable consideration, and is limited to the fairness, from a financial point of view, to the Public Shareholders of JB Chemicals of the Ratios provided for in the Scheme and no opinion or view is expressed with respect to any consideration received in connection with the Proposed Transaction by the holders of any other class of securities, creditors or other constituencies of any party. In addition, no opinion or view is expressed with respect to the fairness (financial or otherwise) of the amount, nature or any other aspect of any compensation to any of the officers, directors or employees of any party to the Proposed Transaction, or class of such persons, relative to the Ratios. Furthermore, no opinion or view is expressed as to the relative merits of the Proposed Transaction in comparison to other strategies or transactions that might be available to JB Chemicals or in which JB Chemicals might engage or as to the underlying business decision of JB Chemicals to proceed with or effect the Proposed Transaction. Further, JB Chemicals will remain solely responsible for the commercial assumptions on which this opinion is based and for its decision to proceed with the Proposed Transaction.

Further, our opinion does not take into account any corporate actions of JB Chemicals after the date hereof, including payment of dividends. We are not expressing any opinion as to what the value of the Equity Shares actually will be when issued or the prices at which the Equity Shares will trade at any time, including following announcement or consummation of the Proposed Transaction. In addition, we express no opinion or recommendation as to how any shareholder, creditor or other person should vote or act in connection with the Proposed Transaction or any related matter. In addition, we are not

expressing any view or opinion with respect to, and have relied, with the consent of JB Chemicals, upon the assessments of representatives of JB Chemicals regarding, legal, regulatory, accounting, tax and other matters relating to the Company, any of their respective subsidiaries and/or associates, as applicable, or any other entity and the Proposed Transaction (including the contemplated benefits of the Proposed Transaction) as to which we understand that JB Chemicals obtained such advice as it deemed necessary from qualified professionals.

We have also assumed that all aspects of the Proposed Transaction and any other transaction contemplated in the Scheme would be in compliance with applicable laws and regulations, and we have issued this opinion on the understanding that we would not in any manner verify, or be responsible for ensuring, such compliance, including without limitation, compliance with the provisions of SEBI Regulations. We understand that the acquisition of shares held by Tau Investment Holdings Pte. Limited in JB Chemicals by Torrent Pharma would trigger an open offer under the Securities Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended. Without prejudice to the generality of the foregoing, we express no opinion and have assumed that the Proposed Transaction will not trigger any additional obligation to make open offers under the Securities Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended and accordingly, we have not considered the consequences or impact on ICICI Securities, if any such offers are mandated, and we have also assumed that the Proposed Transaction will not result in any adverse effect on ICICI Securities or its business, whether under tax or other laws or under the terms of any license or approval.

We have acted as financial advisor to the Board of Directors of JB Chemicals to render this opinion and will receive a fee for our services, which will be paid upon the rendering of this opinion. In addition, JB Chemicals has agreed to reimburse our expenses (subject to certain restrictions) and indemnify us against certain liabilities arising out of our engagement.

We and our affiliates comprise a full-service securities firm and commercial bank engaged in securities, commodities and derivatives trading, foreign exchange and other brokerage activities, and principal investing as well as providing investment, corporate and private banking, asset and investment management, financing and financial advisory services and other commercial services and products to a wide range of companies, governments and individuals. In the ordinary course of our businesses, we and our affiliates may invest on a principal basis or on behalf of customers or manage funds that invest, make or hold long or short positions, finance positions or trade or otherwise effect transactions in equity, debt or other securities or financial instruments (including derivatives, bank loans or other obligations) of JB Chemicals and their respective subsidiaries, joint ventures, associates and/or affiliates.

We and our affiliates in the past have provided, currently are providing, and in the future may provide, investment banking, commercial banking and other financial services to JB Chemicals and its subsidiaries, joint ventures, associates and/or affiliates, and have received or in the future may receive compensation for the rendering of these services.

It is understood that this letter is for the benefit and use of the Board of Directors of JB Chemicals (in its capacity as such) in connection with and for purposes of its evaluation of the Proposed Transaction and is not rendered to or for the benefit of, and shall not confer rights or remedies upon, any person other than the Board of Directors of JB Chemicals. This opinion may not be disclosed, referred to, or communicated (in whole or in part) to any third party, nor shall any public reference to us be made, for any purpose whatsoever except (i) with our prior written consent in each instance; (ii) as required to be disclosed by JB Chemicals to the Stock Exchanges pursuant to applicable laws and may be disclosed



on the website of JB Chemicals and the Stock Exchanges to the extent required under applicable laws and further may also be made a part of the explanatory statement to be circulated to the shareholders and/or creditors of JB Chemicals; and (iii) as required to be disclosed to relevant judicial, regulatory or government authorities, in each case only as may be mandatorily required by applicable laws. Our opinion is necessarily based on financial, economic, monetary, market and other conditions and circumstances as in effect on, and the information made available to us as of, the date hereof. It should be understood that subsequent developments may affect this opinion, and we do not have any obligation to update, revise, or reaffirm this opinion.

RATIONALE & CONCLUSION

In the circumstances, having regard to all relevant factors and on the basis of information and explanations given to us, we are of the opinion on the date hereof, that the Share Exchange Ratio for the merger of JB Chemicals with Torrent Pharma as stated above and recommended by the Registered Valuer is fair.

Yours faithfully,

For ICICI Securities Limited

(SEBI Registration Code for the Merchant Banker: MB/INM000011179)



Raghavan Subramanian
Head – Structured Products
ICICI Securities, Mumbai
Date: 29 June 2025